Patients not already receiving buprenorphine can receive the first injection of Sublocade following a single dose of transmucosal buprenorphine and a 1 hour observation period to confirm tolerability.

The Food & Drug Administration (FDA) announced its approval of an injectable form of buprenorphine (brand name: Sublocade), a medication used to treat opiate addiction. Sublocade releases a steady ...

Canoga Park, California, June 02, 2025 (GLOBE NEWSWIRE) -- Aegis Treatment Centers, part of the Pinnacle Treatment Centers Family of Companies, a leader in providing evidence-based care for ...

Earnings call Indivior reported 2025 net revenue of $1.24B (+4% YoY) and record SUBLOCADE revenue of $856M (+13% YoY), with adjusted EBITDA up 20%. For 2026, management guides for mid-teens SUBLOCADE ...

CEO Mark Crossley stated that Q1 financial results were in line with expectations, despite a 6% year-on-year decline in total net revenue, largely driven by intensified competition in SUBOXONE Film ...

Guidance for 2025 projects total net revenue between $955M and $1.25B, reflecting a decline from 2024 due to erosion in SUBOXONE Film net revenue and the discontinuation of PERSERIS. SUBLOCADE’s 2025 ...